Cargando…
Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast MRI
Multiple targeted therapeutics for Huntington's disease are now in clinical trials, including intrathecally delivered compounds. Previous research suggests that CSF dynamics may be altered in Huntington's disease, which could be of paramount relevance to intrathecal drug delivery to the br...
Autores principales: | Rodrigues, Filipe B., Byrne, Lauren M., De Vita, Enrico, Johnson, Eileanoir B., Hobbs, Nicola Z., Thornton, John S., Scahill, Rachael I., Wild, Edward J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618296/ https://www.ncbi.nlm.nih.gov/pubmed/30687961 http://dx.doi.org/10.1111/ejn.14356 |
Ejemplares similares
-
Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease
por: Byrne, Lauren M., et al.
Publicado: (2018) -
Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease
por: Rodrigues, Filipe B., et al.
Publicado: (2021) -
Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease
por: Ou, Zhen-Yi Andy, et al.
Publicado: (2021) -
Characterizing White Matter in Huntington's Disease
por: Gregory, Sarah, et al.
Publicado: (2019) -
Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington’s disease
por: Lowe, Alexander J, et al.
Publicado: (2022)